Latest News and Press Releases

Autolus announced the online publication of five abstracts submitted to the American Society of Hematology (ASH) Annual Meeting.

Autolus will report third quarter 2025 financial results and business updates on November 12, 2025.

Data from a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosus will be presented.

The first patient has been dosed in the Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) in patients with progressive multiple sclerosis.

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus announces the publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025.

Autolus announced its operational and financial results for the second quarter ended June 30, 2025.

Autolus will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025.

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization

LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and...